Mark Hopman Sells 36,870 Shares of Beta Bionics (NASDAQ:BBNX) Stock

Beta Bionics, Inc. (NASDAQ:BBNX) insider Mark Hopman sold 36,870 shares of the firm’s stock in a transaction that occurred on Wednesday, September 9th. The stock was sold at an average price of $18.46, for a total transaction of $680,620.20. Following the sale, the insider owned 87,157 shares in the company, valued at approximately $1,608,918.22. This trade represents a 29.73% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Mark Hopman also recently made the following trade(s):

• On Wednesday, September 2nd, Mark Hopman sold 5,327 shares of Beta Bionics stock. The shares were sold at an average price of $19.11, for a total value of $101,798.97.
• On Wednesday, June 24th, Mark Hopman sold 1,258 shares of Beta Bionics stock. The stock was sold at an average price of $15.01, for a total value of $18,882.58.

Beta Bionics Stock Down 0.1%

BBNX stock opened at $16.57 on Friday. Beta Bionics, Inc. has a 52-week low of $8.80 and a 52-week high of $32.71. The stock’s fifty day simple moving average is $17.29 and its 200-day simple moving average is $13.80. The stock has a market capitalization of $745.48 million, a price-to-earnings ratio of -10.04 and a beta of 3.37.

Beta Bionics (NASDAQ:BBNX) last released its earnings results on Wednesday, July 29th. The company reported ($0.53) EPS for the quarter, beating the consensus estimate of ($0.62) by $0.09. Beta Bionics had a negative return on equity of 26.30% and a negative net margin of 61.31%.The firm had revenue of $32.01 million during the quarter. As a group, analysts anticipate that Beta Bionics, Inc. will post -2.1 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms have weighed in on BBNX. Weiss Ratings raised shares of Beta Bionics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, August 18th. Bank of America dropped their price objective on Beta Bionics from $23.00 to $11.00 and set a “neutral” rating for the company in a report on Monday, May 18th. William Blair started coverage on Beta Bionics in a research report on Friday, August 21st. They issued a “market perform” rating on the stock. UBS Group began coverage on Beta Bionics in a research report on Tuesday, July 28th. They issued a “buy” rating and a $22.00 target price on the stock. Finally, The Goldman Sachs Group lifted their target price on Beta Bionics from $17.00 to $19.00 and gave the company a “buy” rating in a report on Wednesday, July 15th. Seven research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $20.10.

More Beta Bionics News

Here are the key news stories impacting Beta Bionics this week:

• Neutral Sentiment: Reported short interest was zero as of September 10, offering no evidence that elevated short selling is driving the recent weakness; however, the figures may reflect incomplete or anomalous reporting.
• Negative Sentiment: Multiple law firms reminded shareholders of a November 3, 2026 deadline to seek lead-plaintiff status in a federal securities class action covering purchases made from July 30, 2025, through February 24, 2026. The repeated notices increase the visibility of the litigation risk, although they largely represent competing announcements about the same case. Beta Bionics class action deadline notice
• Negative Sentiment: The lawsuit alleges that Beta Bionics and certain executives misled investors about the iLet system’s safety, efficacy, and regulatory status. Claims reportedly concern an FDA Warning Letter, quality-management-system non-conformities, and allegedly undisclosed customer complaints involving potentially life-threatening hypoglycemia. These are allegations and have not been proven in court. Beta Bionics shareholder alert and allegations
• Negative Sentiment: Insider Mark Hopman sold 36,870 shares for approximately $680,620, reducing his holdings by about 29.7%. The transaction was executed under a pre-arranged Rule 10b5-1 plan, which limits—but does not eliminate—the negative signaling effect. SEC insider-sale filing

Hedge Funds Weigh In On Beta Bionics

A number of hedge funds have recently made changes to their positions in the business. Summit Securities Group LLC acquired a new position in shares of Beta Bionics during the fourth quarter worth about $52,000. Caitong International Asset Management Co. Ltd grew its stake in shares of Beta Bionics by 1,075.7% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,987 shares of the company’s stock valued at $61,000 after buying an additional 1,818 shares in the last quarter. Strs Ohio purchased a new stake in shares of Beta Bionics during the 1st quarter valued at about $29,000. Legal & General Group Plc purchased a new stake in shares of Beta Bionics during the 2nd quarter valued at about $62,000. Finally, CIBC Private Wealth Group LLC lifted its position in Beta Bionics by 630,000.0% during the 4th quarter. CIBC Private Wealth Group LLC now owns 6,301 shares of the company’s stock worth $192,000 after acquiring an additional 6,300 shares in the last quarter.

About Beta Bionics

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.